STAT+: Eli Lilly’s experimental diabetes drug reduced weight and blood sugar in clinical trial
Eli Lilly said Thursday that a study showed its experimental diabetes drug, tirzepatide, reduced patients’ blood sugar and body weight more than a rival medicine, Novo Nordisk’s Ozempic.
Investors had been nervously awaiting the result, which was reported in a press release.
